Idiopathic hypersomnia: clinical features and response to treatment.
OBJECTIVE
A recent American Academy of Sleep Medicine publication identified a need for research regarding idiopathic hypersomnia. We describe various clinical and polysomnographic features of patients with idiopathic hypersomnia, with an emphasis on response to pharmacotherapy.


METHODS
A retrospective review of our database initially identified 997 patients, utilizing "idiopathic hypersomnia", "hypersomnia NOS", and "primary hypersomnia" as keywords. The charts of eligible patients were examined in detail, and data were abstracted and analyzed. Response to treatment was graded utilizing an internally developed scale.


RESULTS
Eighty-five patients were ultimately identified (65% female). Median (interquartile range) ages of onset and diagnosis were 19.6 (15.5) and 33.7 (15.5), respectively. During a median follow-up duration of 2.4 (4.7) years, 65% of patients demonstrated a "complete response" to pharmacotherapy as assessed by the authors' grading schema. Methylphenidate was most commonly used as a first-line agent prior to December 1998, but subsequently, modafinil became the most common first drug. At the last recorded follow-up visit, 92% of patients were on monotherapy, with greater representation of methylphenidate versus modafinil (51% vs. 32%). Among these patients, methylphenidate produced a higher percentage of "complete" or "partial" responses than modafinil, although statistical significance was not reached (38/40 [95%] vs. 22/25 [88%], respectively, p = 0.291).


CONCLUSIONS
The majority of patients with idiopathic hypersomnia respond well to treatment. Methylphenidate is chosen more often than modafinil as final monotherapy in the treatment of idiopathic hypersomnia, despite the fact that it is less commonly used initially. Further prospective comparisons of medications should be explored.
Ali
Mohsin
M
Massachusetts General/Brigham & Women's Hospitals, Harvard Medical School, Boston, MA, USA.
Auger
R Robert
RR
Slocumb
Nancy L
NL
Morgenthaler
Timothy I
TI
D056044:Actigraphy / Q000379:methods / Q000706:statistics & numerical data; D000328:Adult; D001559:Benzhydryl Compounds / Q000627:therapeutic use; D002110:Caffeine / Q000627:therapeutic use; D000697:Central Nervous System Stimulants / Q000627:therapeutic use*; D003913:Dextroamphetamine / Q000627:therapeutic use; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D020177:Idiopathic Hypersomnia / Q000175:diagnosis* / Q000188:drug therapy*; D008297:Male; D008694:Methamphetamine / Q000627:therapeutic use; D008774:Methylphenidate / Q000627:therapeutic use; D000077408:Modafinil; D010389:Pemoline / Q000627:therapeutic use; D017286:Polysomnography / Q000379:methods / Q000706:statistics & numerical data; D012189:Retrospective Studies; D012978:Sodium Oxybate / Q000627:therapeutic use; D016896:Treatment Outcome
D001559:Benzhydryl Compounds; D000697:Central Nervous System Stimulants; D008774:Methylphenidate; D002110:Caffeine; D008694:Methamphetamine; D012978:Sodium Oxybate; D010389:Pemoline; D000077408:Modafinil; D003913:Dextroamphetamine
Brain. 1997 Aug;120 ( Pt 8):1423-35
9278632
Sleep. 2007 Oct;30(10):1274-81
17969461
J Clin Sleep Med. 2007 Oct 15;3(6):613-9
17993043
Sleep. 1986 Dec;9(4):519-24
3809866
Sleep. 1981;4(1):23-37
7232969
Psychiatry Clin Neurosci. 1998 Apr;52(2):125-9
9628108
Neurology. 1996 Feb;46(2):393-401
8614501
Sleep. 2007 Dec;30(12):1705-11
18246980
Sleep. 2007 Dec;30(12):1712-27
18246981
Sleep. 1986;9(1 Pt 2):232-42
3704448
Psychiatry Clin Neurosci. 2005 Apr;59(2):194-9
15823167